Source comparison
Sermorelin Side Effects: Study-by-Study Comparison
The table below summarizes adverse event data from published sermorelin trials across different populations and dosing protocols. Understanding how incidence varies by subject type and administration schedule is essential for protocol design. Pediatric GHD (n=
This comparison does not assign a generated winner or score.
- The table below summarizes adverse event data from published sermorelin trials across different populations and dosing protocols. Understanding how incidence varies by subject type and administration schedule is essential for protocol design.
- Pediatric GHD (n=203, ages 6–14)
- 30 mcg/kg SQ daily × 12 months
- Injection-site reaction (23%), flushing (11%), headache (8%)
- Anaphylaxis (0.5%), sustained tachycardia (0.7%)
- 3.4%
- Well-tolerated in treatment-naive children; AE incidence lower with site rotation
- Adult GHD (n=58, ages 23–61)
- 1–2 mg SQ nightly × 6 months
- Joint stiffness (14%), transient hyperglycemia (9%), headache (7%)
- None reported
- 5.2%
- Higher joint-related AEs in adults reflect baseline lower GH reserves and greater fluid sensitivity
- Healthy elderly (n=42, ages 65–78)
- 1 mg SQ 3× weekly × 16 weeks
- Mild edema (12%), flushing (10%), injection-site pain (8%)
- Transient arrhythmia (2.4%)
- 7.1%
- Age-related cardiac considerations require baseline ECG; lower doses (0.5–0.75 mg) showed better tolerability
- Athletic performance study (n=89, ages 19–35)
- 2 mg SQ nightly × 8 weeks
- Headache (16%), transient tachycardia (13%), flushing (11%)
- 4.5%
- Higher-dose protocols in metabolically healthy subjects show dose-dependent AE escalation without proportional efficacy gains
- The pediatric data represents the most robust evidence base. Larger sample size, longer duration, physician-verified endpoints. Adult and elderly studies are smaller and often open-label, which introduces reporting bias. The athletic performance trial used supraphysiological dosing (2 mg nightly is roughly 2× the standard adult replacement dose), which explains the higher headache and tachycardia rates.